Remidio Receives Regulatory Approval in Karnataka for AI-Based Eye Care Tools

These AI solutions are designed to detect glaucoma and age-related macular degeneration (AMD) early in healthcare settings.

Remidio Innovative Solutions has received approval from the State FDA, Karnataka (CDSCO), for its Medios HI (Humanising Intelligence) Glaucoma AI and Medios HI AMD AI tools.

These AI solutions are designed to detect glaucoma and age-related macular degeneration (AMD) early in healthcare settings.

Dr. R. Kim, Chief Medical Officer at Aravind Eye Hospital, Madurai, commented, “The Remidio fundus camera isn't just an imaging device; it's a portable gateway to early detection and prevention of vision-threatening conditions, bringing quality eye care closer to those who need it most.”

The approval follows the success of Medios DR HI, an AI tool for diabetic retinopathy, which impacted nearly 250,000 patients in the past year. The newly approved AI tools for glaucoma and AMD function offline, allowing real-time analysis without internet access.

This capability is handy for providing eye care in remote and underserved areas with limited access to specialized ophthalmic diagnostics.

The Medios HI Glaucoma AI tool analyzes optic nerve head and retinal nerve fiber layer (RNFL) structures, generating heat map reports to detect early signs of referable glaucoma. India, with 12 million glaucoma patients, faces the challenge of over 90% of cases going undiagnosed, often leading to irreversible vision loss. Early detection using AI tools can help address this issue.

The Medios HI AMD AI tool detects early-stage age-related macular degeneration, affecting 2.1% of Indians over 60, or nearly 6.7 million people. The tool supports timely referrals and preventive care by identifying lesions through AI-generated heat maps.

Both tools have been clinically validated across tertiary hospitals, eye institutes, and vision centers, demonstrating high sensitivity and specificity. The Medios HI system allows healthcare providers to screen for glaucoma, AMD, and diabetic retinopathy using Remidio’s FOP NM 10 fundus camera in just a few seconds.

Dr. Anand Sivaraman, CEO and Founding Director of Remidio, said, “The CDSCO's approval of our Medios HI Glaucoma AI and Medios HI AMD AI builds upon the foundation laid by our Medios HI DR AI, which was the first ophthalmic AI software to receive such approval in India.”